AUGUSTUS trial showed that for people with AF and coronary ischemia, apixaban and a P2Y12 inhibitor should be used at the expense of warfarin or dual antiplatelet agents [113,114]. This evidence concerns the gene P2RY12 and atrial fibrillation.